#USA #AI Integration #Salt Lake City #Co-Diagnostics #PCR platform

Co-Diagnostics Reports Full Year 2025 Financial Results

Co-Diagnostics, Inc. (NASDAQ: CODX), a leader in molecular diagnostics, has announced its financial results for the year ending December 31, 2025. This year proved challenging as the company faced a significant decline in revenue from $3.9 million in 2024 to just $0.6 million. The steep drop was mainly attributed to lesser grant revenue, which played a vital role in their earnings. Moreover, operating expenses surged to $50.6 million, marking an increase from $43 million in 2024, primarily due to an $18.9 million non-cash impairment charge related to the revaluation of intangible assets.

The company reported an operating loss of $50.2 million and a net loss of $46.9 million. These results extrapolate to a loss of $35.25 per share, a slight improvement from a loss of $37.22 per share in the previous year. Nonetheless, adjusting for certain financial metrics, the adjusted EBITDA loss was recorded at $28 million, an improvement compared to the previous year's loss of $33.5 million. As of December 31, 2025, Co-Diagnostics held $11.9 million in cash and marketable securities, a significant decline from $29.7 million the previous year.

Business Highlights and Strategic Partnerships

Despite these financial hurdles, Co-Diagnostics successfully closed several offerings to enhance its capital structure, including a $3.8 million offering of 9.62 million shares at an offering price of $0.40 per share and a $7.0 million offering of 12.7 million shares at $0.55 per share. These efforts are part of a broader strategy to advance the company’s diagnostic capabilities and market presence.

Significant advancements were made this year through the CoSara Diagnostics joint venture in India, focusing on regulatory compliance and manufacturing readiness for its leading product, the PCR Pro® instrument. Furthermore, the company entered into a partnership with Arabian Eagle to establish CoMira Diagnostics in Saudi Arabia, with efforts underway to finalize a manufacturing lease.

Co-Diagnostics has also seen ongoing development within its clinical pipeline. The company initiated and progressed clinical evaluations for upper respiratory multiplex tests and made strides in the development of tuberculosis (TB) and HPV tests. A notable highlight includes the integration of AI capabilities into the Co-Dx™ Primer Ai™ platform, thereby strengthening the company's technological ecosystem and expanding its intellectual property portfolio with a newly granted patent in Australia.

Recent Developments and Future Outlook

In recent developments, Co-Diagnostics received a crucial CDSCO license for the manufacturing and sales of the CoSara PCR Pro® instrument in India, unlocking a significant avenue for commercialization. They have also expanded the commercial territory for CoSara Diagnostics across South Asia, including countries like Bangladesh and Pakistan, broadening the regional addressable market to approximately $13 billion.

Towards the end of this financial year, the company began shipments of the PCR Pro® instruments and TB test materials to India, aligning the product offerings with new WHO guidelines for TB testing. Additionally, an international patent grant in Japan will further bolster their intellectual property footprint.

CEO Dwight Egan highlighted the company’s focus on executing multiple initiatives to foster growth, including enhancing their global footprint and preparation for the commercialization of their product platform throughout 2026. As the rates of COVID declined in their clinical studies areas, they are currently preparing for an FDA 510(k) submission focused on flu and RSV tests, potentially incorporating COVID if necessary down the road.

Looking ahead, Co-Diagnostics aims to streamline its regulatory and commercialization processes, particularly with their upper respiratory test, while maintaining a flexible approach to adapt to any evolving health trends. Egan insists that the collective advancements made within clinical studies will open pathways for realizing the full potential of their diagnostic platform.

Conclusion

Co-Diagnostics continues to navigate a challenging landscape while laying down the necessary groundwork for future innovation and growth. With strategic partnerships and continuous technological advancements at the core of their operations, the company remains focused on meeting the changing demands in the diagnostics market as they gear up for 2026 and beyond.